Founder and CEO
Navroze Mehta is the Founder and CEO of New Day Diagnostics. Two initial areas of focus of the company are point of care diagnostic markers for Ovarian and Prostate cancer. He is also the Founder and CEO of Impact Medical Strategies. Impact Medical Strategies is dedicated to promoting technologies that can solve major global medical unmet needs. Its goal is to make widely applicable devices and health care services sustainable, affordable and accessible to all. Navroze is also Founder & CEO of Mela Artisans Inc. (www.melaartisans.com). He co-founded Mela with his daughter Sonali Mehta Rao. Mela Artisans blends traditional handcrafting techniques with contemporary design in home and fashion to promote social uplift in artisan communities.
Navroze received an MBA from Syracuse University and a Bachelor of Commerce degree from Sydenham College at the University of Bombay, India. Navroze has been a member of Young Presidents Organization (YPO) for 20 years, is past chair of the Americas Gateway Chapter, and served as Regional Chair of the Economic Development Network. He is also a past member of the Ashoka Support Network (www.ashoka.org), a leader in the field of social entrepreneurship and has invested in several social impact enterprises.
ALESSANDRO FATATIS, M.D, Ph.D.
Chief Scientific Officer
Dr. Fatatis is Professor of Pharmacology and Pathology at Drexel University College of Medicine and Co-Leader of the Prostate Cancer Program at the Sidney Kimmel Cancer Center of Thomas Jefferson University in Philadelphia. He is an experimental oncologist with 20 years of experience in basic and translational cancer research. Dr. Fatatis’s work is focused on the identification of the cellular and molecular factors dictating the clinical progression of prostate cancer into its more aggressive form, with the ultimate goal of identifying diagnostic markers and novel therapeutics for the effective management of patients with metastatic disease.
A major project in Dr. Fatatis laboratory led to the discovery that targeting the alpha Receptor for Platelet-Derived Growth Factor (PDGFR) with IMC-3G3, a humanized monoclonal antibody generated by ImClone Biosystems, reduced bone metastases by 70% in pre-clinical models. Eli Lilly and Company is currently conducting Phase-II clinical trials worldwide with this antibody, now renamed Olaratumab, for several solid tumors including advanced prostate adenocarcinoma. More recently, Dr. Fatatis has obtained conclusive evidence that a relevant fraction of prostate cancer cells in skeletal metastases lack expression of the Androgen Receptor (AR) and therefore their number and clinical progression cannot be monitored by measuring Prostate Specific Antigen (PSA), which is directly under the transcriptional control of AR.
Dr. Fatatis earned his degrees in Italy and was trained at the NIH and University of Chicago prior to joining Drexel University.
Prem Gurnani has over 15 years of expert proficiency in new product development, clinical laboratory setup, operations and management, reimbursement and payor strategy, and health information technology. He started his career at PerkinElmer, Inc. where he was a leading scientist in the Genetic Screening R&D group that was responsible for successful FDA approval of two newborn screening tests. He then moved to Houston, Texas to start a personalized genetics company, CompanionDx Reference Lab, where he served in various executive positions. Since then, he has helped open three genetics and proteomics clinical labs – InSource Diagnostics, Altru Diagnostics, Inc., and UT Health Science Center where he held senior executive management positions in operations, technology, strategy development and R&D.
Prem currently serves as a consultant for several diagnostics labs and healthcare technology companies. He has authored over 50 publications, including abstracts, posters, presentations, and books. He has also co-authored and served as a co-investigator in multiple grants.
Prem earned his MS in Biomedical Engineering from UTSW Medical Center, Dallas/ UT, Arlington, and extended his education with The Wharton Business School and John Hopkins Bloomberg School of Public Health.
Senior Research Analyst
Senior Analyst, Ms. Kinjal Bhavsar brings to ProCare over 7 years of experience in design and development of biosensors, assays and medical devices. From 2011 to 2015, she held two positions at Shaily Engineering Plastics Limited, both as head of quality assurance and regulatory compliance. During her time at Shaily, she lead the team in development and manufacturing of life saving complex drug delivery devices. Kinjal previously worked as a scientist at Ohmx Corporation, designing and developing assays for detection of prostate cancer, diabetes and myocardial infarction. Prior to Ohmx, Kinjal worked at Capstone therapeutics to develop an immunoassay for AZX-100, a novel therapeutic peptide for smooth muscle relaxation and fibrosis, and for Chrysalin (Thrombin Peptide TP 508), a novel peptide for angiogenesis, revascularization and repair of dermal and musculoskeletal tissues. For her graduate work, she designed and developed a hand held biosensor for early stage detection of multiple sclerosis. Kinjal holds a M.S.E. and a B.S.E. in Bioengineering from the Bio Design Institute at Arizona State University.